Resources

August 8, 2019
We’re thrilled to feature Dr. Hillel Cohen, Executive Director of ScientificAffairs for Sandoz
July 23, 2019
In July of 2018, the U.S. Food and Drug Administration (FDA) released the Biosimilars Action Plan (BAP). At the one year mark, the agency has made significant progress with the BAP, but more can be done to ensure biosimilars are approved as efficiently as possible.
June 26, 2019
Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars Council to talk about biosimilars, their benefits and the hurdles to adoption in the United States.
June 25, 2019
Patent “thicketing” occurs when a brand-name pharmaceutical company accumulates dozens of patents near the end of the product lifecycle under the guise of “innovative” processes or development that warrant additional protections
June 25, 2019
The Association for Accessible Medicines (AAM) Biosimilars Council found that delayed entry of biosimilars due to patenting has cost the U.S. health care system an astounding $7.6 billion in lost savings since 2015.
June 25, 2019
Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars Council to talk about biosimilars, their benefits and the hurdles to adoption in the United States.

Want to keep up to date with the biosimilars industry?

Sign up for Biosimilars Council Newsletter to hear about the field, learn about events, and find out how you can make an impact.

SIGN UP FOR OUR NEWSLETTER